Mutant MHC class II epitopes drive therapeutic immune responses to cancer

Sebastian Kreiter, Mathias Vormehr, Niels van de Roemer, Mustafa Diken, Martin Löwer, Jan Diekmann, Sebastian Boegel, Barbara Schrörs, Fulvia Vascotto, John C. Castle, Arbel D. Tadmor, Stephen P. Schoenberger, Christoph Huber, Özlem Türeci and Ugur Sahin ()
Additional contact information
Sebastian Kreiter: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University
Mathias Vormehr: Research Center for Immunotherapy (FZI)
Niels van de Roemer: Research Center for Immunotherapy (FZI)
Mustafa Diken: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University
Martin Löwer: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University
Jan Diekmann: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University
Sebastian Boegel: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University
Barbara Schrörs: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University
Fulvia Vascotto: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University
John C. Castle: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University
Arbel D. Tadmor: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University
Stephen P. Schoenberger: La Jolla Institute for Allergy and Immunology
Christoph Huber: Research Center for Immunotherapy (FZI)
Özlem Türeci: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University
Ugur Sahin: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University

Nature, 2015, vol. 520, issue 7549, 692-696

Abstract: The authors show that a large fraction of tumour mutations is immunogenic and predominantly recognized by CD4+ T cells; they use these data to design synthetic messenger-RNA-based vaccines specific against tumour mutations, and show that these can reject tumours in mice.

Date: 2015
References: Add references at CitEc
Citations: View citations in EconPapers (8)

Downloads: (external link)
https://www.nature.com/articles/nature14426 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:520:y:2015:i:7549:d:10.1038_nature14426

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature14426

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().